COVID-19

In a recent study, researchers investigated whether adding the anti-inflammatory baricitinib to treatment with the antiviral remdesivir lead to a reduction in the time to recovery in patients hospitalized...

The first at-home COVID-19 collection kit has been approved for adults aged 18 years or older. Find out more about the kit here.

The US Food and Drug Administration advisory committee has voted 17 to 4 in favor of recommending the authorization the Pfizer/BioNTech COVID-19 mRNA vaccine (BNT162b2).

Christian Sandrock, MD, discussed advising your patients on infection prevention, clinical presentations of SARS-CoV-2, and various paths of management for illness.

This COVID-19 roundup discusses the recent approval of a COVID-19 vaccine in the UK and updated guidance from CDC for quarantine time and travel.

The panel released criteria for the emergency use of bamlanivimab in certain populations but has not indicated FDA approval of the treatment.

The practices outlined by the CDC should be considered when COVID-19 and influenza virus are cocirculating based on local data.

A new study evaluated the use of a mathematical model of SARS-CoV-2 transmission to estimate the reduction in effective reproduction number.

In a new study, researchers aimed to better understand the effect of allergies on patients hospitalized with COVID-19.

Although the FDA has recommended the use of remdesivir, the World Health Organization recommends against its use among patients with COVID-19 infection.